Blood pressure (BP) lowering and rosuvastatin use did not prevent cognitive or functional decline in patients at moderate risk for cardiovascular disease, according to the results of the HOPE-3 Trial presented Nov. 13 during AHA 2016.

Jackie Bosch, PhD, et al., evaluated cognitive and functional outcomes following candesartan and rosuvastatin use in 1,626 patients over six years. The primary outcome was a decline in processing speed as determined by a digit symbol substitution test.

The results of the study show that participants across all patient groups demonstrated cognitive and function decline over the 5.6 years of follow-up. There was no difference in the decline between those in the active or control groups for the BP-lowering arm or the cholesterol-lowering arm or the combination. Neither treatment demonstrated any adverse effect on cognition.

The authors of the study conclude that it is not clear if early initiation and longer term treatment may have benefit.

Keywords: AHA16, American Heart Association, AHA Annual Scientific Sessions, Angina, Stable, Blood Pressure, Blood Pressure Determination, Cholesterol, Cognition, Cognition Disorders, Hypotension

< Back to Listings